Several studies reported high EGFR expression in most esophageal cancer patients (>70% in ESCC, 30–60% in EAC); therefore, EGFR-targeted NIR-PIT is ideally suited to treating esophageal cancer and human trials are underway. The gene discussed is EGFR; the disease is esophageal cancer.